iBio, Inc. (NYSEAMERICAN:IBIO) Sees Significant Decline in Short Interest

iBio, Inc. (NYSEAMERICAN:IBIO) was the recipient of a significant decline in short interest in January. As of January 31st, there was short interest totalling 213,800 shares, a decline of 11.7% from the January 15th total of 242,000 shares. Based on an average trading volume of 174,300 shares, the days-to-cover ratio is currently 1.2 days. Currently, 2.3% of the company’s stock are short sold.

iBio Stock Performance

iBio stock traded down $0.17 during trading on Monday, hitting $3.43. 340,429 shares of the company were exchanged, compared to its average volume of 282,388. iBio has a 52 week low of $1.05 and a 52 week high of $4.98. The company has a current ratio of 0.91, a quick ratio of 0.91 and a debt-to-equity ratio of 0.04.

About iBio

iBio, Inc, a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company’s technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein.